NasdaqGS - Nasdaq Real Time Price USD
Scholar Rock Holding Corporation (SRRK)
As of 1:38 PM EST. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.63 | -0.69 | -2.48 | -2.63 |
| Low Estimate | -0.67 | -0.87 | -2.54 | -3.12 |
| High Estimate | -0.58 | -0.61 | -2.37 | -2.13 |
| Year Ago EPS | -0.5 | -0.59 | -1.99 | -2.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 6 | 9 | 9 |
| Avg. Estimate | -- | -- | -- | 22.51M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 140M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | ? | ? | ? | ∞% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.51 | -0.59 | -0.59 |
| EPS Actual | -0.5 | -0.59 | -0.6 | -0.66 |
| Difference | -0.02 | -0.08 | -0.01 | -0.07 |
| Surprise % | -4.99% | -16.54% | -1.82% | -12.19% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.63 | -0.69 | -2.48 | -2.63 |
| 7 Days Ago | -0.58 | -0.67 | -2.33 | -2.36 |
| 30 Days Ago | -0.58 | -0.67 | -2.33 | -2.36 |
| 60 Days Ago | -0.57 | -0.69 | -2.31 | -2.04 |
| 90 Days Ago | -0.58 | -0.69 | -2.31 | -2.04 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 1 | 2 | -- |
| Down Last 7 Days | -- | -- | 1 | 2 |
| Down Last 30 Days | 1 | 1 | 2 | 4 |
Growth Estimates
| CURRENCY IN USD | SRRK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -26.71% | -- | -- | 5.00% |
| Next Qtr. | -17.37% | -- | -- | 12.00% |
| Current Year | -24.37% | -- | -- | 2.10% |
| Next Year | -6.24% | -- | -- | 12.20% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/12/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 10/15/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 10/14/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 10/11/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/8/2024 |
| Maintains | Wedbush: Outperform to Outperform | 10/7/2024 |
Related Tickers
BHVN Biohaven Ltd.
46.50
-0.70%
WVE Wave Life Sciences Ltd.
14.85
+4.16%
RYTM Rhythm Pharmaceuticals, Inc.
59.85
+0.83%
PTGX Protagonist Therapeutics, Inc.
42.58
+4.72%
KROS Keros Therapeutics, Inc.
55.01
+1.61%
CYTK Cytokinetics, Incorporated
48.89
-1.96%
BPMC Blueprint Medicines Corporation
97.83
+3.18%
KRYS Krystal Biotech, Inc.
182.90
+2.70%
MRUS Merus N.V.
44.44
+3.51%
PTCT PTC Therapeutics, Inc.
43.32
+3.24%